1 Great Biotech Stock You Have Never Heard Of
About 90% of drug candidates that enter clinical trials never make it to market. That brutal fact makes the small-cap biotech sector a tough place for investors to put their money to work.
However, one way investors can increase their odds of success is to watch where big pharma companies are putting their own money. After all, if a deep-pocketed drugmaker with massive expertise likes a small biotech enough to throw tens of millions of dollars at it, that should indicate the company is worthy of a closer look.
That's why I think retail investors should get to know Halozyme Therapeutics (NASDAQ: HALO). This commercial-stage biotech has developed an innovative product that makes other drugs more effective. As a result, Halozyme has been able to attract capital from a who's who of pharmaceutical giants that includes Roche, Johnson & Johnson, Eli Lilly, and Bristol-Myers Squibb.
Source: Fool.com
Merck & Co. Inc. Aktie
Die Community bevorzugt klar Merck & Co. Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Das Kursziel von 125 € für Merck & Co. Inc. weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 104.8 € hin.
